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Tumour suppressor p53 is a key regulator in preventing neoplastic transformation 
by inducing cell cycle arrest or death in response to stress-signalling pathways. 
Consequently, p53 is often non-functional during the early stages of cancer 
development through either direct mutation or aberrant expression of negative 
regulators.  
 
PP2Cβ is a protein phosphatase which was recently identified as a negative 
regulator of p53 and cellular senescence. However, the function of PP2Cβ in cancer 
development is not fully understood.  
The aim of this study was to characterise PP2Cβ and its regulation of p53 pathways 
in human cancer cell lines. This aim was split into two objectives. 
 
The first objective was to examine the effects of PP2Cβ on p53 pathways and cell 
proliferation in four cancer cell lines with various genetic backgrounds. A protein 
analysis using western immunoblotting procedures indicates that p53 pathways 
are activated in cell lines expressing wildtype p53 and Ras. Consistent with 
activated p53 pathways, PP2Cβ knockdown significantly reduced proliferation 
rates, which could be attributed to an increased expression of a p53 target gene, 
p21 cell cycle inhibitor. 
 
The second objective was to investigate the mechanisms regulating of PP2Cβ gene 
expression. Previously, p63 was identified as a potential negative regulator of 
PP2Cβ gene expression based on a modular relational database that integrated 
microarray results with a genome-wide search of p53 family member response 
elements. It was therefore hypothesized that p63 could negatively regulate PP2C 
gene expression. Mammalian expression vectors carrying either the p63 or p73 
expression cassette were constructed and PP2Cβ expression was analysed upon 
overexpression of p53 family members (p53, p63 and p73) in two human cancer 
cell lines. A reverse-transcriptase coupled quantitative PCR showed that 




Taken together the results presented here suggest that restoration of tumour 
suppressors such as p53 and Rb activity by PP2C inhibition could be used as a 
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